Dr. Reddy's Enters into a Licensing Agreement with Gilead for Remdesivir
Dr. Reddy's Laboratories has entered into a non-exclusive licensing agreement with Gilead Sciences. The agreement will grant Dr. Reddy’s the right to register, manufacture and sell Gilead’s investigational drug, Remdesivir, a potential treatment for Covid-19, in 127 countries including India.
Remdesivir, an investigational antiviral therapy developed by Gilead, received Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (USFDA) to treat Covid-19. Dr. Reddy’s will receive technology transfer from Gilead for manufacturing of this drug. The Hyderabad, India-based integrated pharmaceutical company said it would need to do the manufacturing scale-up and obtain regulatory approval for marketing of this drug in respective countries.
